Chaitan Khosla

Chaitan Khosla

Marc and Jennifer Lipschultz Director of the Stanford Innovative Medicines Accelerator (IMA)
Mail Code: 0000

Prof. Chaitan Khosla brings his expertise in human health research and his experience in translating academic research to industry to his role at the Stanford Innovative Medicines Accelerator (IMA).

Prof. Khosla received his PhD in Chemical Engineering from the California Institute of Technology. Research in his laboratory focuses on problems where deep insights into enzymology and metabolism can be harnessed to improve human health. Specifically, he is interested in enzymatic assembly lines that synthesize polyketide antibiotics and in the pathogenesis of celiac disease with the goal of discovering therapies for this widespread but overlooked disease. Prof Khosla has co-founded three companies based on this research, including Kosan Biosciences, founded in 1995 and acquired by Bristol-Myers Squibb in 2008; Alvine Pharmaceutics, founded in 2006 and acquired by ImmunogenX in 2016; and Sitari Pharmaceuticals, founded in 2013 and acquired by GlaxoSmithKline in 2019. Khosla is the Wells H. Rauser and Harold M. Petriprin Professor, and a professor of chemical engineering and of Chemistry at Stanford. He was the founding director of Sarafan ChEM-H.